宫颈癌图像引导腔内近距离放疗的分次内剂量学分析
该研究评估宫颈癌图像引导近距离放疗的分次内剂量学变异,对9例患者共38个分次在计划CT与治疗前CBCT间比较。结果显示HRCTV的D90平均变化小,而直肠D2cc显著增加(P=0.001);OAR剂量变异可能导致单次或全程过剂量,提示需再次成像并干预。
要点
- HRCTV的D90分次内平均相对差异为-1.2±4.5%,变化较小。
- 直肠D2cc平均增加9.3±14.6%,差异有统计学意义(P=0.001)。
- OAR剂量变异可能导致单次或全程过剂量,需再次成像并干预。
核心结论
- HRCTV分次内平均剂量学变异小,总EQD2超过85 Gy的可能性高于97%。
- OAR分次内剂量学变异可能导致单次或全程过剂量,需再次成像并干预。
研究设计与样本
- 对9例宫颈癌患者的38个近距离放疗分次,在计划CT与治疗前CBCT间评估分次内剂量学变异。
主要发现
- HRCTV体积和D90的相对差异分别为-2.0±3.3%和-1.2±4.5%。
- 膀胱、直肠、乙状结肠和小肠D2cc变化分别为-0.6±17.1%、9.3±14.6%、7.2±20.5%和1.5±12.6%。
- 仅直肠D2cc显著增加(P=0.001)。
- 6 Gy×5方案下HRCTV物理剂量5%和10%不确定度时,总EQD2低于85 Gy可能性接近0%和3%。
- OAR 4 Gy物理剂量15%和20%不确定度时,总EQD2超过75 Gy可能性约70%,超过80 Gy者不足1%。
关键数值与推荐
- HRCTV D90分次内相对差异-1.2±4.5%。
- 直肠D2cc分次内相对差异9.3±14.6%(P=0.001)。
- 6 Gy×5高剂量率方案下,HRCTV总EQD2低于85 Gy可能性在5%和10%不确定度时接近0%和3%。
- OAR在15%和20%不确定度下,总EQD2超过75 Gy可能性约70%,超过80 Gy不足1%。
临床怎么用
- 治疗前应再次成像检测不利解剖变化,并采取干预以最小化照射剂量。
- 关注OAR分次内剂量变异,降低并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the intra-fractional dosimetric variations of image-guided brachytherapy of cervical cancer. METHODS: A total of 38 fractions (9 patients) undergoing brachytherapy for cervical cancer underwent a CT scanning for treatment planning (planning CT) and a Cone-beam CT (CBCT) scanning immediately prior to delivery (pre-delivery CBCT). The variations of volumes as well as the dosimetric impact from treatment planning to delivery (intra-application) were evaluated. The dose volume histogram parameters including volume, D90 of high-risk clinical target volume (HRCTV) and D2cc of organs at risk (OARs) were recorded. RESULTS: The relative differences (mean ± 1SD) of the volume and D90 HRCTV across the two scans were - 2.0 ± 3.3% and - 1.2 ± 4.5%, respectively. The variations of D2cc for bladder, rectum, sigmoid and small intestine are - 0.6 ± 17.1%, 9.3 ± 14.6%, 7.2% ± 20.5% and 1.5 ± 12.6%, respectively. Most of them are statistically nonsignificant except the D2cc for rectum, which showed a significant increase (P = 0.001). Using 5% and 10% uncertainty of physical dose for HRCTV at a 6 Gy × 5 high-dose-rate schedule, the possibility of total equivalent doses in 2 Gy fractions (EQD2) lower than 85 Gy is close to 0% and 3%, respectively. Performing similar simulation at 15% and 20% uncertainty of a 4 Gy physical dose for OARs, the possibility of total EQD2 dose exceeding 75 Gy is about 70%. Less than 1% of the total EQD2 of OARs would exceed 80 Gy. CONCLUSIONS: Average intra-fractional dosimetric variation of HRCTV was small in an interval of less than 1 h, and the possibility of total EQD2 exceeding 85 Gy is higher than 97%. The intra-fractional dosimetric variations of OARs might result in an overdose for OARs in a single fraction or the whole treatment. It is necessary to detect unfavorable anatomical changes by re-imaging and take interventions to minimize applied doses and reduce the risk of complications.
引用
- Yan J, Zhu J, Chen K, et al. Intra-fractional dosimetric analysis of image-guided intracavitary brachytherapy of cervical cancer. Radiat Oncol. 2021. PMID: 34348758. doi:10.1186/s13014-021-01870-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。